A detailed history of First Horizon Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 2,604 shares of NTLA stock, worth $41,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,604
Previous 2,132 22.14%
Holding current value
$41,664
Previous $58,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$20.02 - $27.22 $9,449 - $12,847
472 Added 22.14%
2,604 $58,000
Q1 2024

Apr 26, 2024

BUY
$23.82 - $32.8 $4,192 - $5,772
176 Added 9.0%
2,132 $58,000
Q4 2023

Feb 06, 2024

SELL
$23.16 - $32.34 $8,986 - $12,547
-388 Reduced 16.55%
1,956 $59,000
Q3 2023

Oct 27, 2023

SELL
$31.62 - $45.78 $25,485 - $36,898
-806 Reduced 25.59%
2,344 $74,000
Q2 2023

Aug 03, 2023

SELL
$34.58 - $46.03 $6,916 - $9,206
-200 Reduced 5.97%
3,150 $128,000
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $166 - $224
-5 Reduced 0.15%
3,350 $124,000
Q4 2022

Feb 10, 2023

BUY
$33.21 - $62.69 $2,656 - $5,015
80 Added 2.44%
3,355 $117,000
Q3 2022

Nov 09, 2022

SELL
$53.92 - $71.7 $12,725 - $16,921
-236 Reduced 6.72%
3,275 $183,000
Q2 2022

Aug 02, 2022

BUY
$38.49 - $76.21 $135,138 - $267,573
3,511 New
3,511 $181,000
Q1 2022

May 10, 2022

SELL
$58.27 - $118.99 $77,324 - $157,899
-1,327 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$100.76 - $138.36 $10,680 - $14,666
106 Added 8.68%
1,327 $156,000
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $47,917 - $63,994
-362 Reduced 22.87%
1,221 $163,000
Q3 2021

Nov 09, 2021

BUY
$132.37 - $176.78 $77,568 - $103,593
586 Added 58.78%
1,583 $212,000
Q2 2021

Aug 09, 2021

SELL
$60.88 - $161.91 $1,339 - $3,562
-22 Reduced 2.16%
997 $161,000
Q1 2021

May 11, 2021

BUY
$46.59 - $83.68 $47,475 - $85,269
1,019 New
1,019 $81,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.22B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.